A statistical model to estimate the impact of a hepatitis A vaccination programme

Vaccine

Volumn 26, Issue 48, 2008, Pages 6157-6164

  Oviedo, Manuel ^a,b   Pilar Munoz M ^a,c   Domínguez, Angela ^a,d   Borras, Eva ^a   Carmona, Gloria ^b  

^a CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^b Directorate of Public Health   (Spain)

^c UNIVERSITAT POLITÈCNICA DE CATALUNYA   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Count data; Generalized linear models; Hepatitis A vaccine; Incidence; Log linear models; Negative binomial distribution; Overdispersion; Poisson distribution; Statistical models

Indexed keywords

HEPATITIS A VACCINE;

ADOLESCENT; ADULT; ARTICLE; HEALTH PROGRAM; HEPATITIS A; HEPATITIS B; HUMAN; INCIDENCE; MATHEMATICAL COMPUTING; NONHUMAN; POISSON DISTRIBUTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SCHOOL CHILD; SPAIN; STATISTICAL MODEL;

ADOLESCENT; ADULT; AGE FACTORS; ALGORITHMS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; FORECASTING; HEPATITIS A; HEPATITIS A VACCINES; HUMANS; IMMUNIZATION PROGRAMS; INFANT; MALE; MODELS, STATISTICAL; POPULATION; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS; YOUNG ADULT;

EID: 55249092204     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.08.066     Document Type: Article

References (32)

1. Fiore A.E., Wasley A., and Bell B.P. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 55 RR-7 (2006) 1-23
2. Crowcroft N.S., Walsh B., Davison K.L., and Gungabissoon U. Guidelines for the control of hepatitis A virus infection. Commun Dis Public Health 4 (2001) 213-227
3. Ciocca M. Clinical course and consequences of hepatitis A infection. Vaccine 18 Suppl. 1 (2000) S71-S74
4. Wasley A., Fiore A., and Bell B.P. Hepatitis A in the era of vaccination. Epidemiol Rev 28 (2006) 101-111
5. Rosenthal P. Cost-effectiveness of hepatitis A vaccination in children, adolescents, and adults. Hepatology 37 (2003) 44-51
6. Dominguez A., Vidal J., Bruguera M., and Salleras L. Epidemiología de las hepatitis víricas. Enferm Infecc Microbiol Clin 13 Suppl. 1 (1995) 50-61
7. CDC. Prevention of hepatitis A through active or passive immunization. MMWR 55 RR-7 (2006) 16-17
8. Steffen R. Changing travel-related global epidemiology of hepatitis A. Am J Med 118 Suppl. 10A (2005) S46-S49
9. Innis B.L., Snitbhan R., Kunasol P., Laorakpongse T., Poopatanakool W., Kozik C.A., et al. Protection against hepatitis A by an inactivated vaccine. JAMA 271 (1994) 1328-1334
10. Werzberger A., Mensch B., Kuter B., Brown L., Lewis J., Sitrin R., et al. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med 327 (1992) 453-457
11. Dominguez A., Salleras L., Carmona G., and Batalla J. Effectiveness of a mass hepatitis A vaccination program in preadolescents. Vaccine 21 (2003) 698-701
12. Last J.M. A dictionary of epidemiology (2001), Oxford University Press, Oxford
13. Hardin J.W., and Hilbe J.M. Generalized linear models and extensions. Second ed. (2007), Stata Press
14. Armstrong G.L., and Bell B.P. Hepatitis A virus infections in the United States: model-based estimates and implications for childhood immunization. Pediatrics 109 (2002) 839-845
15. Rao ASRS, Chen MH, Pham BZ, Tricco AC, Gilca V, Dubal B, et al. Cohort effects in dynamic models and their impact on vaccination programmes: an example from Hepatitis A BMC Infectious Diseases 2006;6:174. (http://www.biomedcentral.com/1471-2334/6/174).
16. Bauch C.T., Rao A.S.R.S., Pham B.Z., Krahn M., Gilca V., Duval B., et al. A dynamic model for assessing universal hepatitis A vaccination in Canada. Vaccine 25 (2007) 1719-1726
17. Domínguez A., Oviedo M., Carmona G., Batalla J., Salleras L., and Plasència A. Impact and effectiveness of a hepatitis A vaccination programme of preadolescents seven years after introduction. Vaccine 26 (2008) 1737-1741
18. Institut d'Estadística de Catalunya (IDESCAT). Informació territorial: Banc d'estadístiques de municipis i comarques. Idescat 2007. (http://www.idescat.net/cat/poblacio/poblestructura.html).
19. Oviedo M., Munoz M.P., Dominguez A., and Carmona G. Estimated incidence of hepatitis A virus infection in Catalonia. Ann Epidemiol 16 (2006) 812-819
20. Venables W.N., and Ripley B.D. Modern applied statistics with S. Third ed. (2002), Springer
21. McCullagh P., and Nelder J.A. Generalized linear models. Second ed. (1989), Chapman & Hall/CRC
22. Borrás E., Domínguez A., Batalla J., Torner N., Cardeñosa N., Nebot M., et al. Vaccination coverage in indigenous and immigrant children under 3 years of age in Catalonia (Spain). Vaccine 25 (2007) 3240-3243
23. Departament de Salut. Resum de les malalties de declaració obligatoria a Catalunya durant l'any 2003. Butlletí Epidemiològic de Catalunya 1999;XX: 119-33.
24. Samandari T., Bell B.P., and Armstrong G.L. Quantifying the impact of hepatitis A immunization in the United States, 1995-2001. Vaccine 22 (2004) 4342-4350
25. Wasley A., Samandari T., and Bell B.P. Incidence of hepatitis A in the United States in the era of vaccination. JAMA 294 (2005) 194-201
26. Zhou F., Shefer A., Weinbaum C., McCauley M., and Kong Y. Impact of hepatitis A vaccination on health care utilization in the United States, 1996-2004. Vaccine 25 (2007) 3581-3587
27. Jacobsen K.H., and Koopman J.S. The effects of socioeconomic development on worldwide hepatitis A virus seroprevalence patterns. Int J Epidemiol 34 (2005) 600-609
28. Dagan R., Amir J., Mijalovsky A., Bar-Yocahi A., Thoelen S., Safary A., et al. Immunization against hepatitis A in the first year of life: priming despite the presence of maternal antibody. Pediatr Infect Dis J 19 (2000) 1045-1052
29. Werzberger A., Kuter B., and Nalin D. Six years' follow-up after hepatitis A vaccination. N Engl J Med 338 (1998) 1160
30. MacIntyre C.R., Burgess M.A., Hull B., and McIntyre P.B. Hepatitis A vaccination options for Australia. J Paediatr Child Health 39 (2003) 83-87
31. Goldstein S.T., Zhou F., Hadler S.C., Bell B.P., Mast E.E., and Margolis H.S. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol 34 (2005) 1329-1339
32. Taylor R.M., Davern T., Fontana R.J., et al. Fulminant hepatitis A virus infection in the United States: incidence, prognosis, and outcomes. Hepatology 44 (2006) 1589-1597